Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | NGS: changes in CLL management

Richard Rosenquist • 23 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia

Richard Rosenquist Brandell, MD, of Karolinska Institute, Solna, Stockholm, discusses how the management of chronic lymphocytic leukemia (CLL) has changed since the advent of next-generation techniques as well as gene panel assays currently used for CLL prognosis and resistance assesment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Richard Rosenquist

1:50
The impact of IGHV mutational status in treatment decisions in CLL
Richard Rosenquist • 7 Oct 2022
1:26
Common genetic tests in CLL & when these tests should be performed
Richard Rosenquist • 7 Oct 2022
1:31
Using genomics to better understand the pathogenesis of CLL & for early disease diagnosis
Richard Rosenquist • 7 Oct 2022
1:38
The importance of TP53 in CLL
Richard Rosenquist • 7 Oct 2022

Related Videos

1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals